Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research

被引:87
作者
Bae, Jason W. [1 ]
Guyer, William [2 ]
Grimm, Kristy [3 ]
Altice, Frederick L. [1 ]
机构
[1] Yale Univ, Sch Med, Infect Dis Sect, AIDS Program, New Haven, CT USA
[2] Gilead Sci Inc, Foster City, CA 94404 USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
关键词
adherence; antiretroviral medication; HIV/AIDS; measurement; persistence; retention in care; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; SINGLE-DOSE NEVIRAPINE; DRUG-RESISTANCE; TREATMENT INTERRUPTIONS; INITIAL HAART; DISCONTINUATION; ADHERENCE; PHARMACOKINETICS; DURABILITY;
D O I
10.1097/QAD.0b013e328340feb0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Persistence, continuous treatment with a prescribed medication or intervention, is an important, but underrecognized aspect of medication treatment, especially for HIV. In contrast to adherence, which measures the percentage of patient behavior to a prescribed therapy, persistence measures the duration during which a patient remains on a prescribed therapy. Decreased persistence for HIV treatment, or shorter duration on therapy, is associated with increased rates of virological failure, development of antiretroviral resistance, and increased morbidity and mortality. Additionally, frequency and duration of nonpersistent episodes rather than adherence may be a better predictor of clinical outcomes in HIV-infected patients on certain regimens. In this review, we codify the constructs of persistence and adherence, and further define persistence as either patient or regimen persistence. Furthermore, current literature on the clinical consequences of and factors associated with suboptimal persistence is summarized. Finally, methods to measure persistence as well as interventions that may improve persistence and clinical outcomes are suggested. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:279 / 290
页数:12
相关论文
共 71 条
[1]
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the women's interagency HIV study [J].
Ahdieh-Grant, L ;
Tarwater, PM ;
Schneider, ME ;
Anastos, K ;
Cohen, M ;
Khalsa, A ;
Minkoff, H ;
Young, M ;
Greenblatt, RM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (04) :500-503
[2]
Altice FL., 2007, CLIN INFECT DIS, V45, P770, DOI DOI 10.1086/521166
[3]
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs [J].
Altice, Frederick L. ;
Kamarulzaman, Adeeba ;
Soriano, Vincent V. ;
Schechter, Mauro ;
Friedland, Gerald H. .
LANCET, 2010, 376 (9738) :367-387
[4]
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial [J].
Ananworanich, J ;
Nuesch, R ;
Le Braz, M ;
Chetchotisakd, P ;
Vibhagool, A ;
Wicharuk, S ;
Ruxrungtham, K ;
Furrer, H ;
Cooper, D ;
Hirschel, B .
AIDS, 2003, 17 (15) :F33-F37
[5]
[Anonymous], 2009, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, P1
[6]
Lopinavir/ritonavir as single-drug therapy for maintenance of HlV-1 viral suppression -: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study) [J].
Arribas, JR ;
Pulido, F ;
Delgado, R ;
Lorenzo, A ;
Miralles, P ;
Arranz, A ;
González-García, JJ ;
Cepeda, C ;
Hervás, R ;
Paño, JR ;
Gaya, F ;
Carcas, A ;
Montes, ML ;
Costa, JR ;
Peña, JM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :280-287
[7]
Accessing Antiretroviral Therapy Following Release From Prison [J].
Baillargeon, Jacques ;
Giordano, Thomas P. ;
Rich, Josiah D. ;
Wu, Z. Helen ;
Wells, Katherine ;
Pollock, Brad H. ;
Paar, David P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (08) :848-857
[8]
A paradigm shift to prevent HIV drug resistance [J].
Bangsberg, David R. .
PLOS MEDICINE, 2008, 5 (05) :695-696
[9]
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy [J].
Bangsberg, DR ;
Moss, AR ;
Deeks, SG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :696-699
[10]
High levels of adherence do not prevent accumulation of HIV drug resistance mutations [J].
Bangsberg, DR ;
Charlebois, ED ;
Grant, RM ;
Holodniy, M ;
Deeks, SG ;
Perry, S ;
Conroy, KN ;
Clark, R ;
Guzman, D ;
Zolopa, A ;
Moss, A .
AIDS, 2003, 17 (13) :1925-1932